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Abstract  21 
The contemporarily circulation of multiple Bluetongue virus (BTV) serotypes or 22 
strains within the same territory, can imply the co-infection of the ruminant and/or the vector 23 
populations. As a consequence, the clinical and pathological outcomes of the co-infection as 24 
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well as the biological properties of the viral progenies could be influenced and suffer of 25 
relevant variations.  26 
In this study, two independent experiments of co-infections were realized in calves 27 
using European strain of BTV serotype 1 and 8 (BTV-1 and BTV-8, respectively), with the 28 
objective to study their clinical and virological outcomes in comparison with BTV-1 and 29 
BTV-8 single infections.  30 
Synchronous co-infections using the same titre for the two viral strains were 31 
performed and the clinical signs were quantified using a standardized clinical form. Serotype-32 
specific real-time RT-PCRs and viral isolation were used to monitor the course of viraemia. 33 
Neutralizing antibody titres were measured along the experiments, and necropsy with viral 34 
detection in the affected organs was performed.  35 
BTV-8 was detected in the EDTA-blood as well as in the organs of co-infected calves, 36 
while BTV-1 viraemia was inconstant. In parallel, the development of viraemia and high titres 37 
of anti-BTV-1 neutralizing antibodies in calves after BTV-1 single infection proved that the 38 
inoculum was infectious and the detection protocols were efficient.  39 
Several hypotheses could explain the predominant detection of BTV-8 in the co-40 
infected calves, such as the occurrence of a privileged BTV-8 segment 2 reassortment, like 41 
recently described during in vitro BTV-1/BTV-8 co-infections, the interference between the 42 
two viral strains or a higher BTV-8 tropism for the bovine species.  43 
 44 
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1. Introduction 50 
Bluetongue disease in domestic and wild ruminants is caused by bluetongue virus 51 
(BTV) a member of the Orbivirus genus in the Reoviridae family (Mertens et al., 2005). BTV 52 
is a non-enveloped virus with a genome composed of 10 linear segments of dsRNA encoding 53 
for eleven distinct virus proteins (Mertens et al., 2005; Ratinier et al., 2011). BTV is 54 
characterised by great genetic and antigenic variability. At the time of writing, 26 distinct 55 
serotypes have been identified (Hofmann et al., 2008; Maan et al., 2007, 2011). BTV serotype 56 
8 (BTV-8) emerged in Northern and Central Europe in August 2006 and it was characterized 57 
by a high virulence in sheep and, notably, in the bovine populations (Guyot et al., 2008). 58 
During its progressive radial distribution, its co-circulation with BTV serotype 1 (BTV-1) 59 
occurred in Spain and in the South of France. In numerous outbreaks, BTV-1 and BTV-8 60 
were contemporarily detected, which implied the infection of the ruminant population with 61 
both viruses. Co-infection with two BTV serotypes or strains can lead to several biological 62 
consequences, such as variations of the clinical and pathological outcomes in the different 63 
susceptible species, or genetic rearrangements within the viral populations during the 64 
replication in the co-infected host. Reassortment and recombination are both phenomena 65 
which have been proved to occur for BTV in the field (He et al., 2010; Maan et al., 2012). 66 
Recently, a field reassortant strain between BTV-1 and BTV-8 has been identified, through 67 
full-genome sequencing, and its biological properties have been studied in vitro in comparison 68 
to its parental viruses (Shaw et al., 2012).  69 
In this study, two independent experiments of co-infections were realized in calves 70 
using European isolates of BTV-1 and BTV-8, with the objective to study their clinical, 71 
virological and immunological outcomes in comparison with BTV-1 and BTV-8 single 72 
infections.  73 
 74 




2. Materials and Methods 76 
2.1 First in vivo co-infection 77 
Four 12 months-old female Holstein calves have been used in this study. Before the 78 
beginning of the experiment, the calves were tested to confirm their naïve condition towards 79 
BTV, bovine viral diarrhea virus (BVDV) and Bovine herpesvirus 1 (BoHV-1). Furthermore, 80 
a veterinarian was attesting their healthy condition after a detailed clinical examination. The 81 
calves were confined in an insect-secure zone at the Experimental Infectiology Platform 82 
(PFIE) of the INRA center of Tours (Nouzilly, France). The local ethical committee approved 83 
the experimental protocol (dossier n. 2011-10-1).  84 
The calves were divided in two groups of two animals, one being an environmental 85 
control group and another being infected. After one week of acclimatization, the infection was 86 
performed with 10
6
 TCID50 of BTV-1 and an equal dose of BTV-8. The infection was 87 
performed in the neck, subcutaneously (SC) and intravenously (IV). The BTV-8 strain 88 
BEL2006/01 was used, and the origin and the passage history of this strain have been 89 
published elsewhere (Martinelle et al., 2011; Toussaint et al., 2007b). The BTV-1 strain was 90 
kindly provided by Dr. Bernd Hoffmann from the Friedrich-Loeffler-Institut (FLI) 91 
(Eschbaumer et al., 2011). Only four days after the co-infection, Dr. Hoffmann found out that 92 
the BTV-1 inoculum was contaminated with BTV serotype 15 (BTV-15) (Eschbaumer et al., 93 
2011).  94 
The animals were monitored daily by a veterinarian for the duration of the experiment 95 
(21 days). A standardized clinical form was used during the examination of the animals 96 
(Saegerman et al., 2008) which was performed as previously described (Dal Pozzo et al., 97 
2009a). A daily clinical score and a cumulative score at the end of the experiment were 98 
calculated for each animal. The average of the cumulative score was used to compare the two 99 
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groups. After 21 days post-infection (PI), animals were euthanized following an IV injection 100 
of pentobarbital. Spleen, prescapular and mesenteric lymph nodes, were collected and stored 101 
at -80°C for viral RNA detection. 102 
2.2 In vitro kinetic growth of BTV serotypes 103 
In order to compare the in vitro growth properties of the three BTV serotypes used in 104 
the first in vivo co-infection, their kinetic of replication was compared using VERO cell 105 
culture. First, plaque-purified BTV-1 and BTV-15 were obtained. Confluent 6-well microtiter 106 
plates (1×10
6







of the inoculum (infected cell culture supernatant received from the FLI).  Plaque assay was 108 
performed as described by Matsuo and Roy (2009). BTV isolates were obtained following a 109 
plaque-picking method. After five sequential passages of the two plaque-purified viruses on 110 
VERO cells, the absence of any residual contamination was verified by BTV-1 and BTV-15 111 
specific real-time RT-PCR. The virus titres of the two stocks were determined by the end-112 
point dilution assay (Reed and Muench, 1938) and expressed as TCID50/ml.   113 
Plaque-purified and titrated BTV-1 and BTV-15, together with the original BTV-8 114 
inoculum employed in this first experiment, were used in a one-step growth assay, with 115 
confluent VERO cells, a multiplicity of infection (m.o.i.) of 0.02 and following a protocol 116 
previously described (Matsuo et al., 2011). After 0, 4, 8, 12, 20, 28, 48 and 72 hours 117 
incubation, the supernatant was removed and stored at -80°C. For each time point PI the virus 118 
titre was determined in triplicate by the end-point dilution assay (Reed and Muench, 1938) 119 
and expressed as TCID50/ml. For the three tested viruses the final titre was expressed as the 120 
median value of the three replications.     121 
2.3 Second in vivo co-infection 122 
Nine 6 months-old male Holstein calves have been used in this study and the same 123 
inclusion criteria used in the first experiment were verified. The calves were confined in an 124 
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insect-secure zone in the biosafety level 3 animal house of the CODA-CERVA (Machelen, 125 
Belgium). The experiments were approved by the local ethical committee (dossier n. 110228-126 
01). The calves were divided in three groups of three animals: mock-infected calves, BTV-1 127 
single infection, and BTV-1/BTV-8 co-infection. After two weeks of acclimatization, the 128 
infection was performed with 10
6
 TCID50 of virus (the group of co-infected calves received a 129 
dose of 2×10
6
 TCID50). The infection was performed in the neck, SC and IV. Mock-infected 130 
calves received 1 ml of uninfected cell culture supernatant SC and IV. Prior to the second 131 
experiment, BTV-1 and BTV-8 inocula were tested to exclude other serotype contaminations.    132 
The animals were monitored for 35 days using the same protocol described for the first 133 
experiment. Similarly, euthanasia and necropsy were performed.  134 
2.4 Laboratory analysis 135 
2.4.1 BTV detection in biological samples  136 
During the first and the second in vivo experiment, EDTA-blood samples were 137 
collected daily and stored at -80°C. These samples were used to detect the levels of viraemia 138 
by serotype-specific real-time RT-PCR, according to Vandenbussche and co-authors (2009) 139 
for BTV-1 and BTV-8, and Eschbaumer and co-authors (2011) for BTV-15. The construction 140 
of plasmid standard curves allowed the expression of the detected serotype-specific Segment 141 
2 (Seg-2) RNA in copy number/µl, and within the same group of calves, the median value 142 
was calculated. Bovine beta-actin was contemporarily amplified as internal control (Toussaint 143 
et al., 2007a).  144 
BTV RNA detection by the serotype-specific real-time RT-PCR was also performed 145 
from the organs collected during the two necropsies, as previously described (Martinelle et 146 
al., 2011). The detected serotype-specific Seg-2 RNA was expressed in copy number/µl. 147 
In order to detect viable infectious virus in the bloodstream during the viraemic peak, 148 
EDTA-blood samples of the first experiment (3, 6, 8, 10, 12, 15 and 18 days PI) as well as of 149 
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the second experiment (9, 13 and 17 PI), were used for BTV isolation on ECEs (Bréard et al., 150 
2003). In case of embryonic death between 24 hours and 5 days PI, the homogenized embryo 151 
tissues were used for RNA extraction and BTV-1, BTV-8 and BTV-15 specific real-time PCR 152 
were used to identify the isolated viral strain(s).   153 
2.4.2 Serological analysis 154 
For serological analysis, whole blood was collected daily. It was centrifuged at 3000 155 
rpm for 10 minutes and the serum was stored subsequently at -20°C. Neutralizing anti-BTV-156 
1, BTV-8 and BTV-15 VP2 antibodies were searched in the sera of the calves of the first 157 
experiment at several time-points (days 0, 6, 9, 13, 15, 18 and 21 PI). In the second 158 
experiment, only neutralizing anti-BTV-1 and BTV-8 VP2 antibodies were searched (at days 159 
0, 7, 16, 29 PI). The method used to detect and measure the anti-BTV neutralizing antibodies 160 
has been previously described (Martinelle et al., 2011). The median titre of the anti-BTV 161 
neutralizing antibodies within the same group of calves was calculated. 162 
3. Results and discussion 163 
To the authors’ knowledge, this is the first report of experimental in vivo co-infections 164 
of bovines with BTV-1 and BTV-8 European isolates.    165 
The first in vivo experiment was characterized by the accidental triple co-infection of 166 
the calves. A posteriori, using a BTV-1 and a BTV-15 specific real-time RT-PCR 167 
(Eschbaumer et al., 2011; Vandenbussche et al., 2009), BTV-1 and BTV-15 Seg-2 RNA were 168 




copies/µl, respectively in the original BTV-1 169 
inoculum. The co-infected calves did not show hyperthermia, while other typical signs of 170 
bluetongue disease were present such as conjunctivitis, congestion of the dental pad with 171 
erosions and ulcers and congestion of the interdigital area (data not shown). The average of 172 
the cumulative score obtained by the group of co-infected calves was significantly higher 173 
compared to the control group (Fisher Exact Test P<0.001) (Fig. 1A). While control calves 174 
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were constantly negative, an increasing detection of BTV RNA started as soon as the first day 175 
PI in the blood of co-infected calves (Fig. 2A). While BTV-8 Seg-2 RNA was predominant, 176 
BTV-1 Seg-2 RNA was detected inconstantly, and always lower than 10 copies/µl, which is 177 
close to the limit of detection of the real-time (Vandenbussche et al., 2009). BTV-15 Seg-2 178 
RNA was never detected in the bloodstream (Fig. 2A). In the course of viraemia, the 179 
significantly higher detection of Seg-2 BTV-8 RNA (comparison of the daily median values 180 
Seg-2 RNA number of copies/µl by two-factor ANOVA with repeated measures on one 181 
factor, P=0.001) was associated with the exclusive isolation of BTV serotype 8. BTV-8 182 
isolation was obtained from the blood of both co-infected calves and the mean percentage of 183 
BTV-8 positive embryos/day is shown in Fig. 2A. The dominance of BTV-8 was further 184 
confirmed by the development of anti-BTV-8 neutralizing antibodies and the absence of 185 
measurable anti-BTV-1 and anti-BTV-15 neutralizing antibodies (data not shown). 186 
Furthermore, only Seg-2 BTV-8 RNA was detected in the organs of the co-infected calves (in 187 
average, 3.5×10
3 
copies/µl in the spleen, 17 copies/µl and 5 copies/µl in the in the prescapular 188 
and mesenteric lymph-node, respectively). An interesting finding in one of the co-infected 189 
calves and confirmed also after histological examination, was the presence of a localized 190 
haemorrhage attacking 1/3 of the pulmonary artery wall.  191 
The lack of evidence of BTV-1 and BTV-15 replication in the co-infected calves 192 
during the first in vivo experiment was surprising and a first hypothesis, i.e. different dynamic 193 
of replications of the three involved viruses, was formulated. The in vitro kinetic growth of 194 
the three BTV serotypes was evaluated in VERO cells.  The median virus titres measured for 195 
each virus at the different time-points were compared using a two-factor ANOVA with 196 
repeated measures on one factor, showing a significantly different profile of the three kinetic 197 
growth curves (P=0.001) (Fig. 3). Unexpectedly, BTV-1 had an earlier and more abundant 198 
replication during the first 28 hours PI compared to the two other strains. BTV-8, however, 199 
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achieved equal high titres at 48 and 72 hours PI. Because of this efficient in vitro replication, 200 
other factors, than a minor kinetic growth, had to be considered to explain the lack of BTV-1 201 
detection during the first in vivo co-infection. On the contrary, the in vitro assay pointed out a 202 
lower BTV-15 titre at all time-points tested (Fig. 3) and, together with the BTV-15 1 Log10 203 
lower virus titre in the inoculum, it could represent a useful element of explanation of the lack 204 
of replication of this viral strain in vivo.   205 
Because of the accidental BTV-15 contamination, a second in vivo co-infection was 206 
performed. The second experiment was characterized by the inclusion of a group of calves 207 
infected only with BTV-1. Previously, BTV-8 single infections had been performed using the 208 
same viral inoculum and the same experimental protocol (age and bovine breed, viral titre and 209 
inoculation route, clinical examination, BTV-8 RNA detection and isolation in the course of 210 
viraemia, anti-BTV-8 neutralizing antibodies) (Martinelle et al., 2011). The clinical signs 211 
shown by BTV-8 calves after single infection were previously described (Martinelle et al., 212 
2011), while here we report the average of the cumulative clinical score (Fig. 1C). Calves 213 
after BTV-1 single infection had a one-two day hyperthermia (between 39.6 and 40.4°C), oral 214 
congestion (together with ptyalism in one case) and conjunctivitis (data not shown). Co-215 
infected calves had a similar transient hyperthermia, oral congestion and erosions at the dental 216 
pad and internal lips, conjunctivitis (data not shown). The comparison of the average 217 
cumulative clinical scores revealed the absence of significant difference between the group of 218 
calves with BTV-1 single infection and BTV-1 and BTV-8 co-infection (Pearson's chi-219 
squared test, P=0.813) (Fig. 1B). BTV-8 single infection attained the highest average 220 
cumulative clinical score compared to BTV-1 single infection and BTV-1 and BTV-8 co-221 
infection. This finding is consistent with the more severe clinical outcomes observed during 222 
BTV-8 natural infections in bovines during the 2006-2008 epidemic in Europe, compared to 223 
other BTV strains and serotypes, and in particular to BTV-1 during its circulation in Spain 224 
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and in France since 2006 and 2007, respectively (Allepuz et al., 2010; Dal Pozzo et al., 225 
2009b). In the course of both BTV-1 and BTV-8 single infections, calves developed viraemia, 226 
but the comparison of the median values of Seg-2 RNA (Log10 number of copies/µl) detected 227 
in the two groups, showed a significantly earlier detection of BTV-8 viraemia, which lasted 228 
until the end of the experiment, while BTV-1 viraemia was already over 16 days PI (Fig. 2B 229 
and 2C). In co-infected calves only BTV-8 viraemia was constantly detected and lasted until 230 
the end of the experiment, however, the median values of BTV-8 Seg-2 RNA (Log10 number 231 
of copies/µl), measured after the second week PI, were significantly lower compared to the 232 
group of calves with BTV-8 single infection (two-factor ANOVA with repeated measures on 233 
one factor, P=0.001) (Fig. 2B and 2C). Only in 2 out of the 3 co-infected calves and only at 234 
some sporadic days PI, BTV-1 Seg-2 RNA could be detected (at the limit of detection of the 235 
real-time RT-PCR) (data not shown). Interestingly and unlike previously observed during the 236 
first in vivo co-infection, the attempts to isolate BTV in ECE from the blood of co-infected 237 
calves, allowed the isolation of BTV-8 as well as BTV-1. Several ECE, used to isolate BTV 238 
from EDTA-blood samples collected at day 9 and 13 PI, were co-infected with both viruses, 239 
although BTV-8 confirmed to be predominant (Fig 2B).  240 
Compared to the first experiment, in the second in vivo co-infection anti-BTV-1 241 
neutralizing antibodies could be measured, although their titre was significantly lower than 242 
anti-BTV-8 neutralizing antibodies (data not shown). After BTV-1 single infection, Seg-2 243 
BTV-1 RNA was detected only in the prescapular lymph-nodes of the three calves (at the 244 
limit of detection of the real-time RT-PCR), while after BTV-8 single infection, the viral 245 
RNA could be detected in the spleen and in the mesenteric lymph-nodes as well (Martinelle et 246 
al., 2011). These results highlight another interesting difference between BTV-1 and BTV-8 247 
infection in bovine, such as a possible serotype-specific distribution of the two viruses in the 248 
organs.  In the co-infected calves, Seg-2 BTV-8 RNA was detected in the spleen (at the limit 249 
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of detection), and in the prescapular lymph-nodes (20 copies/µl) together with Seg-2 BTV-1 250 
RNA (at the limit of detection).  251 
One of the main findings of both in vivo experiments was the disequilibrium in the 252 
detection of BTV-8 compared to BTV-1 (and BTV-15 in the first experiment). During the 253 
triple co-infection, BTV-8 was the only virus detected, on the contrary, in the absence of 254 
BTV-15, also BTV-1 was found (isolation during viraemia and development of anti-BTV-1 255 
neutralizing antibodies). Viral interference can have an influence on the biological features of 256 
the future viral progeny in the course of co-infection. Nevertheless, while it has been 257 
described during synchronous co-infections between influenza virus strains (Wanitchang et 258 
al., 2012) and between influenza and Newcastle disease virus (Ge et al., 2012), viral 259 
interference occurred in vitro during asynchronous co-infections between BTV strains (Ramig 260 
et al., 1989). In this study, synchronous co-infections were performed, and concerning BTV-1 261 
and BTV-8, equal viral titres were used. Recently, Shaw and co-authors (2012) presented the 262 
results of in vitro co-infections with BTV-1 and BTV-8 European strains. These authors 263 
showed that reassortant viruses could be generated in vitro and that the majority derived Seg-264 
2 from their BTV-8 parental virus (Shaw et al., 2012). In our study, only serotype-specific 265 
real-time RT-PCRs have been used to detect BTV-1, BTV-8 and BTV-15, meaning that the 266 
detection of these strains was dependent to the frequency of the Seg-2. If, reassortment is a 267 
frequent event (Shaw et al., 2012; Ramig et al., 1989), we could hypothesize that the highest 268 
detection of BTV-8 Seg-2 during the first and the second in vivo co-infections was a 269 
consequence of a privileged reassortment of this segment within the viral population. This last 270 
hypothesis requires further investigations, but it represents a fascinating perspective allowing 271 
to confirm a previous in vitro observation. In the event that reassortment could not be proved 272 
and all the other segments would have the same BTV-8 origin, another possible explanation 273 
would be the highest efficiency of the BTV-8 strain used in this study (BTV-8 isolated during 274 
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the 2006 outbreak in Belgium) to infect bovines. The reasons underneath could be numerous, 275 
such as a difference in viral kinetic during in vivo replication, that could occur in various 276 
phases of the viral cycle such as a highest affinity of this BTV-8 strain for bovine receptors, 277 
or a faster in vivo replication cycle providing a dominance of BTV-8 over BTV-1 facilitated 278 
by an interference mechanism.  279 
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 373 
Figure captions 374 
Figure 1 375 
The average cumulative scores, obtained after the cumulative sum of the clinical scores 376 
attributed to the calves of the same group, are presented for the first and the second in vivo 377 
experiment (respectively, A and B) and the BTV-8 single infection (C). The infected groups 378 
of calves are presented together with the correspondent control group. In A, calves were 379 
euthanized 21 days PI.  380 
Figure 2 381 
Viraemia was monitored during the first and the second in vivo experiment 382 
(respectively, A and B) and the BTV-8 single infection (C). In A, calves were euthanized 21 383 
days PI. The median values of the number of copies of BTV-1, BTV-8 and BTV-15 Seg-2 384 
RNA (in Log10) detected in the blood at different days PI, are shown.  385 
The numbers next to some points along the curves, indicate the mean percentage of 386 
ECE with positive BTV isolation starting from the blood collected the same day PI.  387 
Figure 3 388 
In vitro kinetic growth of BTV-1, BTV-8 and BTV-15. The virus titres (in Log10 of 389 
TCID50/ml) are expressed as the median values of three results obtained independently. 390 
391 
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